125 related articles for article (PubMed ID: 10827334)
1. Ovarian function during use of Nestorone(R) subdermal implants.
Brache V; Massai R; Mishell DR; Moo-Young AJ; Alvarez F; Salvatierra AM; Cochon L; Croxatto H; Robbins A; Faundes A
Contraception; 2000 Mar; 61(3):199-204. PubMed ID: 10827334
[TBL] [Abstract][Full Text] [Related]
2. Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
Brache V; Mishell DR; Lahteenmaki P; Alvarez F; Elomaa K; Jackanicz T; Faundes A
Contraception; 2001 May; 63(5):257-61. PubMed ID: 11448466
[TBL] [Abstract][Full Text] [Related]
3. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
Fraser IS; Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR; Apter D; Gale J; Tsong YY; Sivin I
Contraception; 2005 Jul; 72(1):40-5. PubMed ID: 15964291
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial with Nestorone subdermal contraceptive implants.
Díaz S; Schiappacasse V; Pavez M; Zepeda A; Moo-Young AJ; Brandeis A; Lähteenmäki P; Croxatto HB
Contraception; 1995 Jan; 51(1):33-8. PubMed ID: 7750282
[TBL] [Abstract][Full Text] [Related]
5. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
[TBL] [Abstract][Full Text] [Related]
6. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
7. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
8. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.
Croxatto HB; Brache V; Massai R; Alvarez F; Forcelledo ML; Pavez M; Cochon L; Salvatierra AM; Faundes A
Contraception; 2006 Jan; 73(1):46-52. PubMed ID: 16371294
[TBL] [Abstract][Full Text] [Related]
10. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
Laurikka-Routti M; Haukkamaa M
Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
[TBL] [Abstract][Full Text] [Related]
11. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel.
Davies GC; Feng LX; Newton JR; Van Beek A; Coelingh-Bennink HJ
Contraception; 1993 Mar; 47(3):251-61. PubMed ID: 8462316
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women.
Brache V; Merkatz R; Kumar N; Jesam C; Sussman H; Hoskin E; Roberts K; Alami M; Taylor D; Jorge A; Croxatto H; Lorange E; Mishell DR; Sitruk-Ware R
Contraception; 2015 Oct; 92(4):289-97. PubMed ID: 26032952
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
14. Correlation of endocrine profiles with bleeding patterns during use of Nestorone contraceptive implants.
Faúndes A; Alvarez F; Brache V; Cochón L; Tejada AS; Moo-Young A
Hum Reprod; 1999 Dec; 14(12):3013-7. PubMed ID: 10601089
[TBL] [Abstract][Full Text] [Related]
15. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
16. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women.
Massai MR; Díaz S; Quinteros E; Reyes MV; Herreros C; Zepeda A; Croxatto HB; Moo-Young AJ
Contraception; 2001 Dec; 64(6):369-76. PubMed ID: 11834236
[TBL] [Abstract][Full Text] [Related]
17. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
[TBL] [Abstract][Full Text] [Related]
19. Bone turnover markers in women participating in a dose-finding trial of a contraceptive vaginal ring releasing Nestorone and estradiol.
Tiedeken M; Westhoff CL; Cohen A; Cremers S; Sitruk-Ware R; Blithe DL;
Contraception; 2019 Jun; 99(6):329-334. PubMed ID: 30871934
[TBL] [Abstract][Full Text] [Related]
20. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
